Atacicept, an investigational BAFF (B-cell activating factor)/APRIL (a proliferation-inducing ligand) dual inhibitor, significantly reduced proteinuria in patients with immunoglobulin A nephropathy ...

A research team has developed a new class of compounds that effectively inhibit both wild-type CDK9 and its drug-resistant ...

Proliferation of CLL cells is restricted to this protective niche, but the underlying mechanism(s) is/are not known. Treatment with BCR pathway inhibitors results in rapid reductions of total ...

Researchers led by Université de Montréal pathology and cell-biology professor Marc Therrien have identified major structural ...

French drugmaker adds Ayvakit and next-gen immunology pipeline in strategic move to dominate rare disease space Sanofi has ...

Everolimus, a novel proliferation inhibitor and immunosuppressive agent, may suppress cardiac-allograft vasculopathy. We conducted a randomized, double-blind, clinical trial comparing everolimus ...

Pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor, was designed to ... are neoplastic diseases resulting in a clonal proliferation of B cells. CLL is the most common ...

Although the benefit/risk of therapeutic inhibition of VSMC proliferation in atherosclerosis is unclear, experimental and human evidence strongly suggests the therapeutic potential of ...

In BRAF-driven melanoma cells treated with BRAF inhibitors, subpopulations of cells escape drug-induced quiescence through a nongenetic manner of adaptation and resume slow proliferation. Here, we ...

Patients with vitiligo experience impacts on quality of life, emerging therapies offer promising prospects for more targeted ...

In some forms of cancer, these enzymes are present in high levels or overactive and inhibiting them can prevent the proliferation of cancer cells. Tyrosine kinase inhibitors therefore provide an ...